Droplet Biosciences, a Cambridge, MA-based biotechnology company providing sensitive cancer diagnostics, raised $8M in Seed funding.
The round was led by The Engine.
The company intends to use the funds to accelerate its development efforts.
Founded in 2021 by CEO Theresa Tribble, and CSO Wendy Winckler, PhD, along with scientific co-founders Jose P. Zevallos, MD, MPH, Eugene N. Myers M.D. Chair of Otolaryngology at the University of Pittsburgh and UPMC, and Aadel Chaudhuri, MD, PhD, Droplet Biosciences leverages lymphatic fluid to provide earlier and sensitive cancer diagnostics. Droplet’s foundational breakthrough is a non-invasive process to access lymph through the collection of surgical drain fluid after tumor resection. Rich in T-cells, proteins, and other biomarkers, this lymphatic fluid can offer insights into the body’s immune response to cancer earlier and with greater sensitivity than blood. The first application is detecting residual disease in head and neck cancer patients immediately after surgery.